Collegium Pharma (Nasdaq: COLL) reported Q4 EPS of ($0.46), $0.01 worse than the analyst estimate of ($0.45).

Financial Outlook

Based on our current operating plans, Collegium expects that its existing cash resources, along with the net proceeds of its January 2016 follow-on offering, will fund its operations into 2018.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.